Conferences

SUO 2024: Biomarkers and Clinical Predictors in RCC December 7, 2024

SUO 2024: Update on Neoadjuvant Therapy Trials in RCC December 7, 2024

SUO 2024: Sexual Dysfunction and Radical Cystectomy December 7, 2024

SUO 2024: Joseph A Smith, Jr. Mentorship Award Lecture December 7, 2024

SUO 2024: Emerging Therapeutics: Combination Therapy in Neoadjuvant Setting December 7, 2024

SUO 2024: ABLE-32: A Randomized, Controlled, Phase IIIB Clinical Trial of Nadofarogene Firadenovec-vcng versus Observation in Patients with Intermediate-risk, Non-muscle Invasive Bladder Cancer December 7, 2024

SUO 2024: Debate – Management of Localized Radiorecurrent Prostate Cancer: Salvage Radical Prostatectomy December 7, 2024

SUO 2024: Debate – Management of Localized Radiorecurrent Prostate Cancer: Salvage Radiotherapy December 7, 2024

SUO 2024: Debate – Management of Localized Radiorecurrent Prostate Cancer: Focal Ablation December 7, 2024

SUO 2024: Sustainability in Prostate Cancer Care December 7, 2024

SUO 2024: Biology of Cancer Metastases December 7, 2024

SUO 2024: Game Changing Team Science December 6, 2024

SUO 2024: Preventing and Managing Long Term Complications of Radical Cystectomy December 6, 2024

SUO 2024: Exploratory Analysis of Post-treatment Outcomes in Patients with Bacillus Calmette-Guerin-unresponsive High-risk, Non-muscle Invasive Bladder Cancer Who Experienced Non-Response to Pembrolizumab Monotherapy in KEYNOTE-057 December 6, 2024

SUO 2024: Setting the Stage: Our Current Options for BCG Unresponsive NMIBC December 6, 2024

SUO 2024: Are We Missing Aggressive Cancer with PSA Screening Alone? Biochemical Recurrence After Radical Prostatectomy: Evidence from the STHLM3 Trial December 6, 2024

SUO 2024: Telehealth and Cancer: Public Policy and Future Directions December 6, 2024

SUO 2024: Novel Approaches to Radiotherapy to Reduce Patient Burden December 6, 2024

SUO 2024: Sexual Satisfaction Despite Sexual Dysfunction December 6, 2024

SUO 2024: Efficacy and Safety of Padeliporfin VTP for Treatment of Low-Grade UTUC: ENLIGHTED Phase 3 study December 6, 2024

Page 1 of 594